sodium iodide [131i] injection ge healthcare 925 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 925 mbq/ ml
sodium iodide [131i] injection ge healthcare 74 mbq/ ml
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - injeksjonsvæske, oppløsning - 74 mbq/ ml
sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq
theracap 131tm -
ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard
slinda 4 mg
exeltis healthcare s.l. (1) - drospirenon - tablett, filmdrasjert - 4 mg
volibris
glaxosmithkline (ireland) limited - ambrisentan - hypertensjon, pulmonal - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.
evkeeza
ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipid modifiserende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).